Goal guide, 2026

Best peptides for Muscle Growth

For muscle growth, the strongest evidence points to Lenomorelin, Liraglutide, and Dulaglutide. Lenomorelin directly stimulates growth hormone secretion, a key driver of muscle protein synthesis and body composition. Liraglutide and Dulaglutide support an anabolic environment by reducing adiposity and improving insulin sensitivity, which indirectly favors lean mass retention. All three carry Grade A evidence ratings based on clinical trial data.

Understanding Muscle Growth with peptides

Muscle growth depends on anabolic signaling pathways, primarily driven by growth hormone, IGF-1, and insulin. Peptides can intervene at several points in this cascade. Ghrelin mimetics like Lenomorelin stimulate pituitary release of growth hormone, which subsequently elevates IGF-1 levels in peripheral tissues. Elevated IGF-1 activates mTOR signaling in skeletal muscle, promoting protein synthesis and satellite cell proliferation. GLP-1 receptor agonists contribute through a different mechanism: by improving insulin sensitivity and reducing systemic inflammation, they create a metabolic environment more permissive to lean mass accrual.

Two peptide classes are most relevant to muscle growth outcomes. The first is growth hormone secretagogues, represented here by Lenomorelin, which directly amplify endogenous GH pulsatility without exogenous hormone administration. The second class is GLP-1 receptor agonists, including Liraglutide, Dulaglutide, Exenatide, Albiglutide, and Lixisenatide. While primarily studied for glycemic control and weight loss, GLP-1 agonists reduce visceral adiposity and hyperinsulinemia, both of which are documented antagonists of skeletal muscle hypertrophy. Reduced fat mass with preserved lean mass is a consistently reported outcome in longer-duration GLP-1 trials.

The evidence base for peptides and muscle growth is stratified. Lenomorelin holds Grade A evidence specifically for GH secretion and appetite stimulation, with secondary data supporting improvements in lean body mass in GH-deficient and aging populations. GLP-1 agonists such as Liraglutide and Dulaglutide have robust Grade A evidence from large cardiovascular outcomes trials, where body composition changes were secondary endpoints. Direct hypertrophy endpoints are less commonly reported in GLP-1 literature, but the mechanistic and indirect data supporting lean mass preservation are well-documented. Researchers evaluating this category should distinguish between direct anabolic effects and supportive metabolic remodeling.

Ranked by evidence (63 found)

Peptide	Evidence	Primary mechanism
Albiglutide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Promotes weight loss via appetite suppression	Research
Cagrilintide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Dose-dependent weight loss in trials	Research
Dulaglutide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Significant weight loss (2-4 kg average)	Research
Exenatide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Promotes weight loss	Research
Lenomorelin	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Stimulates growth hormone secretion	Research
Liraglutide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Promotes significant weight loss	Research
Lixisenatide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Promotes modest weight loss	Research
Macimorelin	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Diagnostic assessment of growth hormone secretory capacity	Research
Retatrutide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Exceptional weight loss (up to 24% body weight)	Research
Semaglutide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Significant weight loss (average 15-20% body weight)	Research
Setmelanotide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Reduces appetite and supports weight management	Research
Tesamorelin	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Supports GH production	Research
Tirzepatide	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	Superior weight loss compared to semaglutide (average 20-25%)	Research
ACE-031	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Increases skeletal muscle mass and strength	Research
AOD-9604	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Supports weight loss	Research
Anamorelin	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Enhances body weight in wasting conditions	Research
CJC-1295	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Increases growth hormone and IGF-1 levels	Research
Capromorelin	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Stimulates growth hormone secretion	Research
Carnosine	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Enhances muscle endurance and exercise capacity	Research
Eloralintide	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Dose-dependent weight loss in trials	Research
Sermorelin	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Increases natural GH production	Research
Tesofensine	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	Promotes weight loss in obesity	Research
Alexamorelin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone secretion	Research
Anserine	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Reduces muscle fatigue and lactate accumulation	Research
Argireline	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Decreases facial muscle contraction intensity	Research
BPC-157	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Repairs tendons, ligaments, and muscle tissue	Research
CJC-1293	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone secretion	Research
Cardiogen	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Supports cardiac muscle function and contractility	Research
Dermorphin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	High receptor binding affinity and selectivity	Research
Follistatin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Dramatic increase in muscle mass	Research
GHRP-1	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone release	Research
GHRP-2	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Potent GH secretagogue	Research
GHRP-3	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone secretion	Research
GHRP-4	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone secretion	Research
GHRP-5	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone release	Research
GHRP-6	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Increases GH and IGF-1 levels	Research
Hexarelin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Very potent GH release	Research
IGF-1 DES	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Promotes localized muscle hypertrophy	Research
IGF-1 LR3	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Promotes significant muscle growth	Research
Ipamorelin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone release	Research
Irisin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Supports mitochondrial biogenesis in muscle	Research
Livagen	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	May improve liver-derived protein synthesis	Research
Lysine-Arginine	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Supports muscle nutrient delivery	Research
MGF	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Promotes localized muscle repair and growth	Research
PEG-MGF	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Promotes muscle fiber repair	Research
Pentapeptide-18	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Reduces facial muscle contractions and wrinkle formation	Research
Snap-8	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Inhibits facial muscle contractions	Research
TB-500	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Reduces inflammation throughout the body	Research
Tabimorelin	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	Stimulates growth hormone secretion	Research
Vesilute	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	May enhance bladder smooth muscle tone	Research
5-Amino-1MQ	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Promotes fat loss and weight reduction	Research
Decapeptide-12	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Evens skin tone and brightens complexion	Research
Desmopressin		Reduces nocturnal polyuria and nighttime urination	Research
Enkephalins (Met-Enkephalin, Leu-Enkephalin)		Modulates pain perception through opioid receptors	Research
Leuphasyl	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Reduces muscle contraction	Research
Melanostatin DM	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Brightens skin tone and evens complexion	Research
Metformin		Supports weight management and fat loss	Research
Myostatin	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Increases skeletal muscle mass and strength	Research
Nonapeptide-1	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Lightens hyperpigmentation and age spots	Research
Pramlintide		May support modest weight loss	Research
Syn-Ake	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Relaxes facial muscles	Research
Vialox	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Relaxes facial muscles non-invasively	Research
YK11	DEvidenceGrade DTheoretical or in-vitro only, with no meaningful independent human evidence	Increases muscle mass and strength	Research

Top picks by evidence grade

Albiglutide

AEvidence

Promotes weight loss via appetite suppression

Cagrilintide

AEvidence

Dose-dependent weight loss in trials

Dulaglutide

AEvidence

Significant weight loss (2-4 kg average)

Exenatide

AEvidence

Promotes weight loss

Getting started

01
Identify Your Physiological Target
Determine whether the primary goal is direct GH-mediated hypertrophy or metabolic optimization to support lean mass. Research suggests these two pathways require different peptide classes, and selecting the wrong category may yield suboptimal outcomes for the specific mechanism being studied.
02
Review Available Clinical Evidence
Prioritize peptides with Grade A evidence such as Lenomorelin for GH secretion or Liraglutide for metabolic body composition changes. Cross-referencing peer-reviewed trial data helps establish realistic expectations for the magnitude and timeline of lean mass effects observed in research populations.
03
Assess Complementary Outcome Markers
Clinical research protocols for muscle growth typically track markers such as IGF-1 levels, lean body mass via DEXA, fasting insulin, and HbA1c alongside primary endpoints. Selecting a peptide with multi-marker relevance, such as Lenomorelin for GH and appetite or Dulaglutide for insulin sensitivity and weight, can provide a more comprehensive picture of anabolic status.

Related side-by-side comparisons

Detailed evidence comparisons for the top muscle growth peptides.

Questions people ask

Do peptides for muscle growth work differently than anabolic steroids?

Yes, the mechanisms are distinct. Peptides like Lenomorelin stimulate the pituitary to release endogenous growth hormone rather than introducing exogenous androgens. GLP-1 agonists improve metabolic conditions rather than directly activating androgen receptors. Research indicates this results in different side effect profiles and a more indirect anabolic stimulus compared to steroidal compounds.

Can GLP-1 agonists genuinely support muscle growth, or do they only cause weight loss?

GLP-1 receptor agonists primarily reduce fat mass, but multiple clinical trials report preservation of lean body mass during weight loss phases when protein intake and resistance activity are maintained. Improved insulin sensitivity, a documented effect of Liraglutide and Dulaglutide, reduces insulin resistance in muscle tissue, which supports glucose uptake and glycogen storage relevant to muscle performance and recovery.

How long does research suggest it takes for peptides to show measurable effects on muscle composition?

Study durations vary by peptide class. GH secretagogue research like Lenomorelin often reports measurable IGF-1 changes within weeks, but lean mass changes in clinical trials typically require 12 to 26 weeks of observation. GLP-1 agonist trials reporting body composition endpoints commonly span 52 weeks or longer, reflecting the slower pace of metabolic remodeling versus direct anabolic stimulation.

Are there peptides that combine appetite stimulation with anabolic signaling for muscle growth research?

Lenomorelin is notable in this context because it simultaneously stimulates growth hormone secretion and increases appetite and food intake, both of which are relevant to supporting a caloric surplus necessary for muscle hypertrophy. This dual mechanism makes it a distinct research candidate compared to GLP-1 agonists, which suppress appetite and are better suited to lean mass preservation during caloric restriction rather than mass accumulation phases.

Not sure where to start?

The goal finder asks three questions and gives you a peptide recommendation ranked by evidence grade.

Use the goal finder Compare peptides

Understanding Muscle Growth with peptides

Ranked by evidence (63 found)

Top picks by evidence grade

Albiglutide

Cagrilintide

Dulaglutide

Exenatide

Getting started

Related side-by-side comparisons

Questions people ask

Do peptides for muscle growth work differently than anabolic steroids?

Can GLP-1 agonists genuinely support muscle growth, or do they only cause weight loss?

How long does research suggest it takes for peptides to show measurable effects on muscle composition?

Are there peptides that combine appetite stimulation with anabolic signaling for muscle growth research?

Not sure where to start?

Explore other goals